View Financial HealthDeva Holding 配当と自社株買い配当金 基準チェック /16Deva Holding配当を支払う会社であり、現在の利回りは0.38%です。主要情報0.4%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Upcoming Dividend • Jun 18Upcoming dividend of ₺0.25 per shareEligible shareholders must have bought the stock before 25 June 2024. Payment date: 27 June 2024. Payout ratio is a comfortable 1.3% but the company is paying out more than the cash it is generating. Trailing yield: 0.2%. Lower than top quartile of Turkish dividend payers (2.3%). Lower than average of industry peers (1.9%).Upcoming Dividend • Apr 04Upcoming dividend of ₺0.15 per shareEligible shareholders must have bought the stock before 11 April 2022. Payment date: 13 April 2022. Payout ratio is a comfortable 1.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (3.8%). Lower than average of industry peers (1.7%).Upcoming Dividend • Apr 05Upcoming dividend of ₺0.10 per shareEligible shareholders must have bought the stock before 12 April 2021. Payment date: 14 April 2021. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (2.5%). Lower than average of industry peers (1.4%).すべての更新を表示Recent updatesBuy Or Sell Opportunity • Apr 08Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at ₺63.50. The fair value is estimated to be ₺52.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Mar 13Deva Holding A.S., Annual General Meeting, Apr 10, 2026Deva Holding A.S., Annual General Meeting, Apr 10, 2026. Location: halkali merkez mahalle basin, ekspres caddesi no.1, istanbul TurkeyReported Earnings • Mar 09Full year 2025 earnings releasedFull year 2025 results: Revenue: ₺19.2b (up 25% from FY 2024). Net loss: ₺807.0m (down ₺876.4m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.New Risk • Nov 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 807% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).Reported Earnings • Nov 09Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₺4.47b (up 22% from 3Q 2024). Net loss: ₺20.8m (loss narrowed 92% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 14% per year.Reported Earnings • Aug 18Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: ₺4.19b (up 23% from 2Q 2024). Net income: ₺499.4m (down 45% from 2Q 2024). Profit margin: 12% (down from 27% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 24% per year.Reported Earnings • May 12First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₺4.19b (up 7.8% from 1Q 2024). Net income: ₺18.4m (up ₺430.0m from 1Q 2024). Profit margin: 0.4% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 13Deva Holding A.S., Annual General Meeting, Apr 14, 2025Deva Holding A.S., Annual General Meeting, Apr 14, 2025. Location: halkali merkez mah. basin ekspres cad. no:1, istanbul TurkeyReported Earnings • Mar 09Full year 2024 earnings releasedFull year 2024 results: Revenue: ₺15.5b (up 36% from FY 2023). Net income: ₺69.4m (down 98% from FY 2023). Profit margin: 0.4% (down from 30% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₺3.66b (up 58% from 3Q 2023). Net loss: ₺266.7m (down 146% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.Reported Earnings • Sep 29Second quarter 2024 earnings released: EPS: ₺0.043 (vs ₺0.10 in 2Q 2023)Second quarter 2024 results: EPS: ₺0.043 (down from ₺0.10 in 2Q 2023). Revenue: ₺2.83b (down 15% from 2Q 2023). Net income: ₺867.3m (down 58% from 2Q 2023). Profit margin: 31% (down from 62% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth.Reported Earnings • Jun 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₺3.58b (up 79% from 1Q 2023). Net loss: ₺379.6m (down 185% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year whereas the company’s share price has increased by 54% per year.Upcoming Dividend • Jun 18Upcoming dividend of ₺0.25 per shareEligible shareholders must have bought the stock before 25 June 2024. Payment date: 27 June 2024. Payout ratio is a comfortable 1.3% but the company is paying out more than the cash it is generating. Trailing yield: 0.2%. Lower than top quartile of Turkish dividend payers (2.3%). Lower than average of industry peers (1.9%).Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₺99.40, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 284% over the past three years.Reported Earnings • May 19Full year 2023 earnings releasedFull year 2023 results: Revenue: ₺11.3b (up 153% from FY 2022). Net income: ₺3.39b (up 149% from FY 2022). Profit margin: 30% (in line with FY 2022).Reported Earnings • Nov 05Third quarter 2023 earnings released: EPS: ₺2.92 (vs ₺1.62 in 3Q 2022)Third quarter 2023 results: EPS: ₺2.92 (up from ₺1.62 in 3Q 2022). Revenue: ₺2.32b (up 101% from 3Q 2022). Net income: ₺584.0m (up 80% from 3Q 2022). Profit margin: 25% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 20Second quarter 2023 earnings released: EPS: ₺4.52 (vs ₺1.54 in 2Q 2022)Second quarter 2023 results: EPS: ₺4.52 (up from ₺1.54 in 2Q 2022). Revenue: ₺1.90b (up 86% from 2Q 2022). Net income: ₺903.1m (up 193% from 2Q 2022). Profit margin: 48% (up from 30% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₺78.00, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 278% over the past three years.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₺59.95, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 204% over the past three years.Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₺48.86, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 160% over the past three years.Reported Earnings • May 07First quarter 2023 earnings released: EPS: ₺2.22 (vs ₺1.76 in 1Q 2022)First quarter 2023 results: EPS: ₺2.22 (up from ₺1.76 in 1Q 2022). Revenue: ₺2.00b (up 127% from 1Q 2022). Net income: ₺444.8m (up 27% from 1Q 2022). Profit margin: 22% (down from 40% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 41% per year.Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₺43.40, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 418% over the past three years.Reported Earnings • Mar 12Full year 2022 earnings releasedFull year 2022 results: Revenue: ₺4.48b (up 92% from FY 2021). Net income: ₺1.36b (up 16% from FY 2021). Profit margin: 30% (down from 50% in FY 2021). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₺43.54, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 290% over the past three years.Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₺68.90, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 678% over the past three years.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sengul Soytas was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 06Third quarter 2022 earnings released: EPS: ₺1.62 (vs ₺0.70 in 3Q 2021)Third quarter 2022 results: EPS: ₺1.62 (up from ₺0.70 in 3Q 2021). Revenue: ₺1.15b (up 118% from 3Q 2021). Net income: ₺324.9m (up 132% from 3Q 2021). Profit margin: 28% (up from 27% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: ₺1.54 (vs ₺0.90 in 2Q 2021)Second quarter 2022 results: EPS: ₺1.54 (up from ₺0.90 in 2Q 2021). Revenue: ₺1.02b (up 99% from 2Q 2021). Net income: ₺308.0m (up 72% from 2Q 2021). Profit margin: 30% (down from 35% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 87% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 08First quarter 2022 earnings released: EPS: ₺1.76 (vs ₺1.12 in 1Q 2021)First quarter 2022 results: EPS: ₺1.76 (up from ₺1.12 in 1Q 2021). Revenue: ₺884.0m (up 61% from 1Q 2021). Net income: ₺351.1m (up 57% from 1Q 2021). Profit margin: 40% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sengul Soytas was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Apr 04Upcoming dividend of ₺0.15 per shareEligible shareholders must have bought the stock before 11 April 2022. Payment date: 13 April 2022. Payout ratio is a comfortable 1.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (3.8%). Lower than average of industry peers (1.7%).Reported Earnings • Mar 06Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₺5.85 (up from ₺3.26 in FY 2020). Revenue: ₺2.33b (up 25% from FY 2020). Net income: ₺1.17b (up 80% from FY 2020). Profit margin: 50% (up from 35% in FY 2020). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 106% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₺31.00, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 716% over the past three years.Buying Opportunity • Feb 24Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be ₺35.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 58% per annum over the last 3 years.Buying Opportunity • Jan 24Now 23% undervaluedOver the last 90 days, the stock is up 24%. The fair value is estimated to be ₺38.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 58% per annum over the last 3 years.Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₺28.22, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 777% over the past three years.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₺29.08, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 732% over the past three years.Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS ₺0.70 (vs ₺0.99 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₺527.2m (up 22% from 3Q 2020). Net income: ₺139.8m (down 29% from 3Q 2020). Profit margin: 27% (down from 46% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS ₺0.90 (vs ₺0.62 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₺513.8m (up 27% from 2Q 2020). Net income: ₺179.5m (up 46% from 2Q 2020). Profit margin: 35% (up from 31% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 09First quarter 2021 earnings released: EPS ₺1.12 (vs ₺0.81 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₺548.4m (up 13% from 1Q 2020). Net income: ₺223.2m (up 38% from 1Q 2020). Profit margin: 41% (up from 33% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Apr 05Upcoming dividend of ₺0.10 per shareEligible shareholders must have bought the stock before 12 April 2021. Payment date: 14 April 2021. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (2.5%). Lower than average of industry peers (1.4%).Reported Earnings • Mar 07Full year 2020 earnings released: EPS ₺3.26 (vs ₺1.43 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₺1.86b (up 36% from FY 2019). Net income: ₺651.4m (up 128% from FY 2019). Profit margin: 35% (up from 21% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Feb 15New 90-day high: ₺33.22The company is up 36% from its price of ₺24.34 on 17 November 2020. The Turkish market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₺31.76, the stock is trading at a trailing P/E ratio of 11.2x, up from the previous P/E ratio of 9.1x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders over the past three years are 645%.Is New 90 Day High Low • Jan 25New 90-day high: ₺28.88The company is up 25% from its price of ₺23.10 on 27 October 2020. The Turkish market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day high: ₺25.84The company is up 31% from its price of ₺19.77 on 09 October 2020. The Turkish market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Nov 11New 90-day high: ₺24.90The company is up 10.0% from its price of ₺22.58 on 13 August 2020. The Turkish market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS ₺0.99The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₺433.6m (up 30% from 3Q 2019). Net income: ₺197.4m (up 218% from 3Q 2019). Profit margin: 46% (up from 19% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Oct 23New 90-day high: ₺22.90The company is up 12% from its price of ₺20.38 on 24 July 2020. The Turkish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Is New 90 Day High Low • Sep 28New 90-day low: ₺18.45The company is down 4.0% from its price of ₺19.25 on 30 June 2020. The Turkish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 DEVAが配当金を支払っている期間は 10 年未満です。増加する配当: DEVAの配当金は増加していますが、同社は6年間しか配当金を支払っていません。配当利回り対市場Deva Holding 配当利回り対市場DEVA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DEVA)0.4%市場下位25% (TR)0.4%市場トップ25% (TR)2.7%業界平均 (Pharmaceuticals)1.9%アナリスト予想 (DEVA) (最長3年)n/a注目すべき配当: DEVAの配当金 ( 0.38% ) はTR市場の配当金支払者の下位 25% ( 0.42% ) と比べると目立ったものではありません。高配当: DEVAの配当金 ( 0.38% ) はTR市場の配当金支払者の上位 25% ( 2.66% ) と比較すると低いです。株主への利益配当収益カバレッジ: DEVAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: DEVAは 現金配当性向 ( 1.7% ) が低いため、配当金の支払いはキャッシュフローによって完全にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YTR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/06 02:54終値2026/05/06 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Deva Holding A.S. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Upcoming Dividend • Jun 18Upcoming dividend of ₺0.25 per shareEligible shareholders must have bought the stock before 25 June 2024. Payment date: 27 June 2024. Payout ratio is a comfortable 1.3% but the company is paying out more than the cash it is generating. Trailing yield: 0.2%. Lower than top quartile of Turkish dividend payers (2.3%). Lower than average of industry peers (1.9%).
Upcoming Dividend • Apr 04Upcoming dividend of ₺0.15 per shareEligible shareholders must have bought the stock before 11 April 2022. Payment date: 13 April 2022. Payout ratio is a comfortable 1.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (3.8%). Lower than average of industry peers (1.7%).
Upcoming Dividend • Apr 05Upcoming dividend of ₺0.10 per shareEligible shareholders must have bought the stock before 12 April 2021. Payment date: 14 April 2021. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (2.5%). Lower than average of industry peers (1.4%).
Buy Or Sell Opportunity • Apr 08Now 21% overvaluedThe stock has been flat over the last 90 days, currently trading at ₺63.50. The fair value is estimated to be ₺52.38, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Mar 13Deva Holding A.S., Annual General Meeting, Apr 10, 2026Deva Holding A.S., Annual General Meeting, Apr 10, 2026. Location: halkali merkez mahalle basin, ekspres caddesi no.1, istanbul Turkey
Reported Earnings • Mar 09Full year 2025 earnings releasedFull year 2025 results: Revenue: ₺19.2b (up 25% from FY 2024). Net loss: ₺807.0m (down ₺876.4m from profit in FY 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
New Risk • Nov 15New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 807% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).
Reported Earnings • Nov 09Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₺4.47b (up 22% from 3Q 2024). Net loss: ₺20.8m (loss narrowed 92% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 14% per year.
Reported Earnings • Aug 18Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: ₺4.19b (up 23% from 2Q 2024). Net income: ₺499.4m (down 45% from 2Q 2024). Profit margin: 12% (down from 27% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year whereas the company’s share price has increased by 24% per year.
Reported Earnings • May 12First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ₺4.19b (up 7.8% from 1Q 2024). Net income: ₺18.4m (up ₺430.0m from 1Q 2024). Profit margin: 0.4% (up from net loss in 1Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 13Deva Holding A.S., Annual General Meeting, Apr 14, 2025Deva Holding A.S., Annual General Meeting, Apr 14, 2025. Location: halkali merkez mah. basin ekspres cad. no:1, istanbul Turkey
Reported Earnings • Mar 09Full year 2024 earnings releasedFull year 2024 results: Revenue: ₺15.5b (up 36% from FY 2023). Net income: ₺69.4m (down 98% from FY 2023). Profit margin: 0.4% (down from 30% in FY 2023). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 10Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₺3.66b (up 58% from 3Q 2023). Net loss: ₺266.7m (down 146% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Sep 29Second quarter 2024 earnings released: EPS: ₺0.043 (vs ₺0.10 in 2Q 2023)Second quarter 2024 results: EPS: ₺0.043 (down from ₺0.10 in 2Q 2023). Revenue: ₺2.83b (down 15% from 2Q 2023). Net income: ₺867.3m (down 58% from 2Q 2023). Profit margin: 31% (down from 62% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 40% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Jun 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: ₺3.58b (up 79% from 1Q 2023). Net loss: ₺379.6m (down 185% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 50% per year whereas the company’s share price has increased by 54% per year.
Upcoming Dividend • Jun 18Upcoming dividend of ₺0.25 per shareEligible shareholders must have bought the stock before 25 June 2024. Payment date: 27 June 2024. Payout ratio is a comfortable 1.3% but the company is paying out more than the cash it is generating. Trailing yield: 0.2%. Lower than top quartile of Turkish dividend payers (2.3%). Lower than average of industry peers (1.9%).
Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₺99.40, the stock trades at a trailing P/E ratio of 5.9x. Average trailing P/E is 26x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 284% over the past three years.
Reported Earnings • May 19Full year 2023 earnings releasedFull year 2023 results: Revenue: ₺11.3b (up 153% from FY 2022). Net income: ₺3.39b (up 149% from FY 2022). Profit margin: 30% (in line with FY 2022).
Reported Earnings • Nov 05Third quarter 2023 earnings released: EPS: ₺2.92 (vs ₺1.62 in 3Q 2022)Third quarter 2023 results: EPS: ₺2.92 (up from ₺1.62 in 3Q 2022). Revenue: ₺2.32b (up 101% from 3Q 2022). Net income: ₺584.0m (up 80% from 3Q 2022). Profit margin: 25% (down from 28% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 20Second quarter 2023 earnings released: EPS: ₺4.52 (vs ₺1.54 in 2Q 2022)Second quarter 2023 results: EPS: ₺4.52 (up from ₺1.54 in 2Q 2022). Revenue: ₺1.90b (up 86% from 2Q 2022). Net income: ₺903.1m (up 193% from 2Q 2022). Profit margin: 48% (up from 30% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₺78.00, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 278% over the past three years.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₺59.95, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 204% over the past three years.
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₺48.86, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 160% over the past three years.
Reported Earnings • May 07First quarter 2023 earnings released: EPS: ₺2.22 (vs ₺1.76 in 1Q 2022)First quarter 2023 results: EPS: ₺2.22 (up from ₺1.76 in 1Q 2022). Revenue: ₺2.00b (up 127% from 1Q 2022). Net income: ₺444.8m (up 27% from 1Q 2022). Profit margin: 22% (down from 40% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 41% per year.
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₺43.40, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 418% over the past three years.
Reported Earnings • Mar 12Full year 2022 earnings releasedFull year 2022 results: Revenue: ₺4.48b (up 92% from FY 2021). Net income: ₺1.36b (up 16% from FY 2021). Profit margin: 30% (down from 50% in FY 2021). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • Feb 13Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₺43.54, the stock trades at a trailing P/E ratio of 5.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 290% over the past three years.
Valuation Update With 7 Day Price Move • Dec 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to ₺68.90, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 678% over the past three years.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sengul Soytas was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 06Third quarter 2022 earnings released: EPS: ₺1.62 (vs ₺0.70 in 3Q 2021)Third quarter 2022 results: EPS: ₺1.62 (up from ₺0.70 in 3Q 2021). Revenue: ₺1.15b (up 118% from 3Q 2021). Net income: ₺324.9m (up 132% from 3Q 2021). Profit margin: 28% (up from 27% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 83% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: ₺1.54 (vs ₺0.90 in 2Q 2021)Second quarter 2022 results: EPS: ₺1.54 (up from ₺0.90 in 2Q 2021). Revenue: ₺1.02b (up 99% from 2Q 2021). Net income: ₺308.0m (up 72% from 2Q 2021). Profit margin: 30% (down from 35% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 87% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 08First quarter 2022 earnings released: EPS: ₺1.76 (vs ₺1.12 in 1Q 2021)First quarter 2022 results: EPS: ₺1.76 (up from ₺1.12 in 1Q 2021). Revenue: ₺884.0m (up 61% from 1Q 2021). Net income: ₺351.1m (up 57% from 1Q 2021). Profit margin: 40% (in line with 1Q 2021). Over the last 3 years on average, earnings per share has increased by 59% per year but the company’s share price has increased by 105% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Sengul Soytas was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Apr 04Upcoming dividend of ₺0.15 per shareEligible shareholders must have bought the stock before 11 April 2022. Payment date: 13 April 2022. Payout ratio is a comfortable 1.7% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (3.8%). Lower than average of industry peers (1.7%).
Reported Earnings • Mar 06Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: EPS: ₺5.85 (up from ₺3.26 in FY 2020). Revenue: ₺2.33b (up 25% from FY 2020). Net income: ₺1.17b (up 80% from FY 2020). Profit margin: 50% (up from 35% in FY 2020). The increase in margin was primarily driven by higher revenue. Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed estimates. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has increased by 106% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₺31.00, the stock trades at a trailing P/E ratio of 8.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 716% over the past three years.
Buying Opportunity • Feb 24Now 26% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be ₺35.34, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 58% per annum over the last 3 years.
Buying Opportunity • Jan 24Now 23% undervaluedOver the last 90 days, the stock is up 24%. The fair value is estimated to be ₺38.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% per annum over the last 3 years. Earnings per share has grown by 58% per annum over the last 3 years.
Valuation Update With 7 Day Price Move • Dec 23Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₺28.22, the stock trades at a trailing P/E ratio of 7.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 777% over the past three years.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₺29.08, the stock trades at a trailing P/E ratio of 8.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in Asia. Total returns to shareholders of 732% over the past three years.
Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS ₺0.70 (vs ₺0.99 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₺527.2m (up 22% from 3Q 2020). Net income: ₺139.8m (down 29% from 3Q 2020). Profit margin: 27% (down from 46% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 91% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS ₺0.90 (vs ₺0.62 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₺513.8m (up 27% from 2Q 2020). Net income: ₺179.5m (up 46% from 2Q 2020). Profit margin: 35% (up from 31% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has increased by 85% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 09First quarter 2021 earnings released: EPS ₺1.12 (vs ₺0.81 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₺548.4m (up 13% from 1Q 2020). Net income: ₺223.2m (up 38% from 1Q 2020). Profit margin: 41% (up from 33% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 100% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Apr 05Upcoming dividend of ₺0.10 per shareEligible shareholders must have bought the stock before 12 April 2021. Payment date: 14 April 2021. Trailing yield: 0.3%. Lower than top quartile of Turkish dividend payers (2.5%). Lower than average of industry peers (1.4%).
Reported Earnings • Mar 07Full year 2020 earnings released: EPS ₺3.26 (vs ₺1.43 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₺1.86b (up 36% from FY 2019). Net income: ₺651.4m (up 128% from FY 2019). Profit margin: 35% (up from 21% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Feb 15New 90-day high: ₺33.22The company is up 36% from its price of ₺24.34 on 17 November 2020. The Turkish market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 23% share price gain to ₺31.76, the stock is trading at a trailing P/E ratio of 11.2x, up from the previous P/E ratio of 9.1x. This compares to an average P/E of 24x in the Pharmaceuticals industry in Asia. Total returns to shareholders over the past three years are 645%.
Is New 90 Day High Low • Jan 25New 90-day high: ₺28.88The company is up 25% from its price of ₺23.10 on 27 October 2020. The Turkish market is up 24% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day high: ₺25.84The company is up 31% from its price of ₺19.77 on 09 October 2020. The Turkish market is up 25% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Nov 11New 90-day high: ₺24.90The company is up 10.0% from its price of ₺22.58 on 13 August 2020. The Turkish market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Reported Earnings • Nov 08Third quarter 2020 earnings released: EPS ₺0.99The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₺433.6m (up 30% from 3Q 2019). Net income: ₺197.4m (up 218% from 3Q 2019). Profit margin: 46% (up from 19% in 3Q 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 65% per year but the company’s share price has increased by 71% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Oct 23New 90-day high: ₺22.90The company is up 12% from its price of ₺20.38 on 24 July 2020. The Turkish market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Sep 28New 90-day low: ₺18.45The company is down 4.0% from its price of ₺19.25 on 30 June 2020. The Turkish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.